BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/18/2026 3:51:54 AM | Browse: 0 | Download: 0
 |
Received |
|
2026-06-17 03:36 |
|
Peer-Review Started |
|
2026-06-17 03:37 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2026-06-29 03:51 |
|
Revised |
|
2026-07-09 16:34 |
|
Publication Fee Transferred |
|
2026-07-14 14:50 |
|
Second Decision by Editor |
|
2026-07-23 07:39 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-07-27 07:30 |
|
Articles in Press |
|
2026-07-27 07:30 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-08-11 00:43 |
|
Publish the Manuscript Online |
|
2026-08-18 03:51 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Age-male-albumin-bilirubin-platelet score stratifies hepatocellular carcinoma risk after sustained virological response in hepatitis C-related compensated advanced chronic liver disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Sirajuk Khongviwatsathien and Tawesak Tanwandee |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Tawesak Tanwandee, MD, Professor, Division of Gastroenterology, Department of Medicine, Siriraj Hospital, Mahidol University, 2 Wanglang Road Bangkoknoi, Bangkok 10700, Thailand. tawesak@gmail.com |
| Key Words |
Hepatitis C virus; Compensated advanced chronic liver disease; Direct-acting antiviral therapy; Sustained virological response; Hepatocellular carcinoma; Age-male-albumin-bilirubin-platelet score; Risk stratification; Surveillance de-escalation |
| Core Tip |
This retrospective cohort study evaluated the age-male-albumin-bilirubin-platelet (aMAP) score for predicting hepatocellular carcinoma (HCC) risk after sustained virological response in patients with hepatitis C virus-related compensated advanced chronic liver disease. Among 571 patients followed for a median of 4.59 years, 78 developed HCC. The aMAP score outperformed other noninvasive scoring systems, and an exploratory threshold of < 55 identified 18.6% of patients with no observed HCC events. These findings suggest that the aMAP score may support individualized surveillance intensity; however, the threshold requires external validation before routine clinical implementation. |
| Publish Date |
2026-08-18 03:51 |
| Citation |
Khongviwatsathien S, Tanwandee T. Age-male-albumin-bilirubin-platelet score stratifies hepatocellular carcinoma risk after sustained virological response in hepatitis C-related compensated advanced chronic liver disease. World J Hepatol 2026; 18(8): 124474
|
| URL |
https://www.wjgnet.com/1948-5182/full/v18/i8/124474.htm |
| DOI |
https://doi.org/10.4254/wjh.124474 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
